中国肺癌杂志2023，Vol.26Issue(12)：901-909,9.DOI:10.3779/j.issn.1009-3419.2023.102.38
外周血免疫指标在肺癌患者免疫治疗中的预测价值
Predictive Value of Peripheral Blood Biomarkers in the Treatment of Lung Cancer Patients with Anti PD-1 Immunotherapy
摘要
Abstract
Background and objective The application of programmed cell death 1(PD-1)/programmed cell death ligand 1(PD-L1)antibodies has greatly improved the clinical outcomes of lung cancer patients.Here,we retrospectively analyzed the efficacy of PD-1 antibody therapy in locally advanced non-surgical or metastatic lung cancer patients,and pre-liminarily explored the correlation between peripheral blood biomarkers and clinical responses.Methods We conducted a single center study that included 61 IIIA-IV lung cancer patients who received PD-1 antibody treatment from March 2020 to December 2021,and collected the medical record data on PD-1 antibody first-line or second-line treatment.The levels of mul-tiple Th1 and Th2 cytokines in the patient's peripheral blood serum,as well as the phenotype of peripheral blood T cells,were detected and analyzed.Results All the patients completed at least 2 cycles of PD-1 monoclonal antibody treatment.Among them,42 patients(68.9%)achieved partial response(PR);7 patients(11.5%)had stable disease(SD);and 12 patients(19.7%)had progressive disease(PD).The levels of peripheral blood interferon gamma(IFN-γ)(P=0.023),tumor necrosis factor α(TNF-α)(P=0.007)and interleukin 5(IL-5)(P=0.002)before treatment were higher in patients of the disease control rate(DCR)(PR+SD)group than in the PD group.In addition,the decrease in absolute peripheral blood lymphocyte count after PD-1 antibody treatment was associated with disease progression(P=0.023).Moreover,the levels of IL-5(P=0.0027)and IL-10(P=0.0208)in the blood serum after immunotherapy were significantly increased compared to baseline.Conclusion Peripheral blood serum IFN-γ,TNF-α and IL-5 in lung cancer patients have certain roles in predicting the clinical efficacy of anti-PD-1 therapy.The decrease in absolute peripheral blood lymphocyte count in lung cancer patients is related to disease progression,but large-scale prospective studies are needed to further elucidate the value of these biomarkers.关键词
肺肿瘤/免疫治疗/生物标志物/疗效预测Key words
Lung neoplasms/Immunotherapy/Biomarkers/Efficacy prediction引用本文复制引用
苏舒,吕昕,祁亮,韦敏,刘宝瑞,王立峰..外周血免疫指标在肺癌患者免疫治疗中的预测价值[J].中国肺癌杂志,2023,26(12):901-909,9.基金项目
本研究受北京医学奖励基金项目(No.YXJL-2020-07230122)和南京市卫健委医学重点科技发展项目(No.ZKX23017)资助 This study was supported by the grants from Beijing Medical Award Foundation(No.YXJL-2020-07230122)and Medical Key Science and Technology Development Project of Nanjing Municipal Health Commission(No.ZKX23017)(Both to Lifeng WANG). （No.YXJL-2020-07230122）
